Travere Therapeutics, Inc. filed 3 current reports with the SEC under Item 5.02, which covers directors and officers leaving or being appointed, the latest on 2026-09-21. Between them they name 4 people, with 2 appointments and 2 departures. Each change below is quoted from the filing and linked to it.
Every change, newest first
Appointed: Bradley L. Campbell, President and Chief Executive Officer
Bradley L. Campbell has been named as Dr. Dube's successor with his appointment as President and Chief Executive Officer and as a member of the Board of Directors to be effective as of the Officer Resignation Date.
Departing: Sandra Calvin
5.02(b) On July 6, 2026, Sandra Calvin, chief accounting officer (CAO) and principal accounting officer (PAO) of the Company, provided notice to the Company of her intention to retire from employment with the Company following the filing of the Company's Annual Report on Form 10-K expected in February 2027 (the "Retirement Date").
Departing: William Rote, Chief Research Officer, effective 2027-02-17
On June 12, 2026, William Rote, Ph.D., Chief Research Officer of the Company, provided notice to the Company of his intention to retire from employment with the Company, effective February 17, 2027 (the "Retirement Date"), the 10 year anniversary of his employment with the Company.
Appointed: Jula Inrig, Chief Medical Officer, effective 2026-07-01
Effective July 1, 2026, Dr. Inrig is being named Executive Vice President, Head of Research & Development and Chief Medical Officer.
Find people with the same kind of experience as the President and Chief Executive Officer at Travere Therapeutics, Inc., with the record behind each one.
Find candidates like President and Chief Executive Officer at Travere Therapeutics, Inc.New leaders review vendors and budgets in their first months. Get an alert the next time Travere Therapeutics, Inc. is in the news or changes leadership.
Get an alert when Travere Therapeutics, Inc. changes leadershipTools for this story
Each opens in a new tab, filled in for Travere Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.